Not Yet RecruitingNot Applicable

Prevalence of Alpha-1 Antitrypsin Deficiency in Non-Cirrhotic Liver Cancer

France71 participantsStarted 2026-01

Plain-language summary

Patients with Alpha-1 Antitrypsin Deficiency (AATD), a rare genetic disease, have a 20- to 50-fold higher risk of developing primary liver cancer (PLC), such as hepatocellular carcinoma (HCC), in both cirrhotic and non-cirrhotic livers, highlighting AATD as a potential oncogenic factor. Therefore, our aim is to evaluate the association between AATD and HCC in patients with a non-cirrhotic liver and no known predisposition

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adult patients (≥18 years of age).
✓. Histopathologically confirmed diagnosis of hepatocellular carcinoma (HCC).
✓. Normal liver or chronic liver disease with minimal to moderate fibrosis in non-tumoral tissue.
✓. Signed informed consent obtained prior to participation.
✓. No other known etiology or risk factors for liver disease, including:

Exclusion criteria

✕. Minor patients (\<18 years of age).
✕. HCC diagnosis not established according to standard histopathological criteria.
✕. Liver with chronic liver disease showing advanced fibrosis in non-tumoral tissue.
✕. No signed informed consent prior to participation.
✕. Presence of other identified etiologies or known risk factors for liver disease, including:

What they're measuring

Prevalence of Alpha-1 Antitrypsin Deficiency

Timeframe: 1 year

Trial details

NCT IDNCT07145385

SponsorUniversity Hospital, Bordeaux

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-09

Contact for this trial

Marie Decraecker, MD

+335 57 65 64 38 marie.decraecker@chu-bordeaux.fr

View on ClinicalTrials.gov More Retrospective Cohort of Patients Diagnosed With HCC on Non-Cirrhotic Liver trials